SMN2 and proximal spinal muscular atrophy: As evidence for narrow therapeutic windows in SMA emerge [34], international guidelines concurrently advocate for intervention within two weeks of diagnostic confirmation in infants identified with two copies of SMN2 and predicted to have a severe phenotype [35].